Mold-Tek Packaging Limited (533080) Earnings Call Transcript
October 29, 2025
Earnings Call Speaker Segments
Good day, everyone, and welcome to the Mold-Tek Packaging Limited earnings conference call, hosted by Emkay Global Financial Services Limited. Just a reminder that all participant lines will be in listen-only mode, and after the presentation wraps up, there will be a chance for you to ask questions. If you need help at any point during this call, please signal an operator by pressing Star then Zero on your touch-tone phone. Please be aware that this conference is being recorded. I'll now turn the conference over to Nitin Gupta from Emkay Global Financial Services Limited. Thank you, and over to you.
Thank you, Hina. Hello, everyone, and good evening. I'd like to extend a welcome to Mr. J. Lakshmana Rao, our Chairman and Managing Director, and express our appreciation to him for letting us host this call. At this point, I'll pass things over to him so he can share his opening remarks. The floor is yours, sir.
Good afternoon, everyone. Thank you so much for joining us for Mold-Tek Packaging Limited's Q2 and H1 results. I'm very pleased to tell you that we've achieved decent volume growth. As all of you are aware, Q2 and Q3 tend to be our low-volume season. Heavy rains over the past four, five months have affected the movement of goods and the sale of certain food products, such as ice creams and yogurts, as well as paints. Even so, we posted a decent 9.65% increase in sales value and roughly 7% in volume terms. EBITDA is also up by around 8.37% versus last Q2. So across H1 overall, we recorded an EBITDA margin of INR 40.6 per kg compared with INR 36.73 last year, which registers a healthy growth of 10.5% in EBITDA terms. What's most heartening and a very good indicator for me is the growth in pharma packaging sales, which rose by a massive 45% compared to Q1. While that figure was INR 7-odd crore in Q1, it has climbed to INR 10+ crore in Q2, which is a 45% growth in pharma packaging sales. So we remain on track to reach our target of INR 35+ crore in pharma, and with a much higher sale price and EBITDA margins.
That's a really encouraging observation for this quarter—besides that, other sectors such as Food & FMCG also posted decent growth. Now I think we can share more information through the question-and-answer session. I'll leave it to the coordinator to begin the Q&A.
Thank you so much. We'll now start the question-and-answer portion. Anybody who would like to ask a question can press Star and One on their touch-tone phone. Should you want to take yourself out of the question queue, you can press Star and Two. We ask that participants use the handset when posing their questions. Ladies and gentlemen, we'll pause briefly while the question queue forms. Our first question comes from the line of Darshita with DSP. Please go ahead. Darshita's connection has dropped. We'll proceed to the following question. The next question comes from the line of Dipak Saha with Nirmal Bang Institutional Equities. Please go ahead.
Hello there. Sir, can you hear me okay?
Yes, that's right.
Sir, I have a couple of questions. In your opening remarks, you said the Goods and Services Tax impact would bring positive things. I just want to understand: for the quarter that just passed, Q2, did the announcement cause any adverse impact — any dispatches delayed — and could your volume number have been affected, or could it have grown much better than what you valued? Just some color on that.
Sure, absolutely. So GST was announced a month back — that's around August, if I recall correctly — and it took effect starting in September. During September there was a bit of a slowdown in momentum, and orders really began coming in only once the GST effect had properly set in. That factor also contributed to a certain quiet period.
All right, so with that in mind, do you think things will recover in Q3 and Q4? Since, if we look at that 42,000 tons of guidance you mentioned earlier, are you still sticking with it despite the shortfall you saw in Q2? Where do you stand at this point? Because then you'd need to go some extra miles in Q3 and Q4, correct? Normally, Q3 and Q4 come in below Q1 figures. On those numbers, to hit 42,000 tons, we have to do somewhat better, a bit on the double-digit side, for Q3 and Q4. Could you give me some sense of where you stand on the volume side for the full year?
Sure. Q2 and Q3 tend to be the low points each year for us, and then Q4 gains steam. That pattern should hold this year as well. Now that GST is being implemented, I think it makes sense to wait and watch. October still looks a lot like September — things are moving somewhat slowly, though we are on the positive side. The indications for November are quite strong. My hope is that November and December will be decent enough to lift us to at least a double-digit growth. On the fourth quarter, I have a lot of confidence, because our Food & FMCG production has already begun in Panipat and some orders have been executed there too. The fourth quarter will definitely get a lift on those two counts. A number of the orders and molds that have been coming in for pharma during this third quarter will turn productive in the fourth quarter. We will be running across those two, three segments. As for paints, it still hinges on the rains and when they stop, since even now there has been a cyclone in Telangana and Andhra for the last two days, extending another couple of days. We are hoping the paint segment begins to pick up. That is the indication given for November. Hopefully we will be back on track to achieve 10% volume growth.
There's another thing I'd like you to notice here. Perhaps we've consistently been discussing volume growth. In this case, the growth is showing up in thin wall and Food & FMCG. Pardon me — pharma. That's the area where component weight and tonnage sold are lower in tons relative to heavy products such as paints — meaning paint and lubricant buckets. So it might appear that volume growth is smaller, but on closer inspection, although volume growth stands at 6.8%, sales revenue growth comes in at 9.65%. That points to better value addition, or improved selling realization, driven by the product mix moving toward food and pharma.
Right, no — that's genuinely useful, sir. Appreciate the thorough response, and it shows up in the figures. Thanks to the shift in mix, the year-over-year realization gain is plainly evident. So only one final question regarding the sweet pack side: the extra capacities we're putting in and expect from Q3 onward ought to lift the F&F figure — the Food & FMCG number — in a positive way overall. You've begun to see that traction on sweet packs, so if you could especially highlight the sweet packs, since realizations and margins would also be comparatively stronger in that category. That would be my final question, sir. Thank you.
Yes. Despite the Goods and Services Tax, sweet packs have gained traction — or regardless of it, I should say. In September and October too, since it's the festive period, demand was quite strong, and we performed pretty well. Production has also begun up north, in Panipat. So the sweet box hasn't really been affected much. Consumers weren't hesitant about purchasing sweets. In that sense, there isn't a significant decline or flattening in demand. Things are going well there. And in the north, we've now signed a few solid contracts with dairies across the Delhi NCR region, and those should start contributing numbers from February onward. As I mentioned, our Food & FMCG growth will be maintained as the Panipat operations ramp up into production.
Yes, that helps, sir. Thank you. And best of luck for the next quarter. Yes.
I appreciate that.
Thanks. Our next question is from Kaivalya Baing at IIFL Capital. You have the floor.
Hello, sir. Thank you for taking my question. First off, congratulations on a solid set of numbers. My question relates to the softness we saw in paints this quarter. As with last quarter, in the first quarter we posted growth of nearly 20%+ in value terms in paints. This quarter, we posted about 3.36%. Could you elaborate on that?
When the rains are everywhere, I really doubt people are going to be painting their houses, offices, or anything else. We saw decent growth in Q1. Q2, though, has been muted. Even with a good jump in ABG numbers, we finished with turnover growth of 2.6%, or volume growth of 3%. That's well below our average of roughly 11% for the six months. This is where the numbers took a hit from the heavy rains over the last four, five months. Paints grew 21% in the last quarter. Now it's barely 3%. That's one of the main drawbacks, I'd say, in pulling volume growth down below 10%. But once the rains stop, demand that's been held back will return, and activity will pick up for the summer and marriage season. I think paint demand should rise starting November, December onwards.
But sir, didn't we also see some seasonal impact in Q1? Even with that, we posted close to 20%+. What exactly would be the likely reason for such a steep drop in growth?
Yes, that’s exactly what I said. Seasonality is one of the biggest factors behind the slower growth versus Q1. The monsoon this time was extremely heavy, and it hit both the paint and lubricant segments — paint managed at least 3% growth, but lubes fell by nearly 13% against Q2 of last year. Naturally, when goods and materials move more slowly during monsoon, lubricant demand suffers. That’s also where packaging is getting hit. But with Food & FMCG, I’m really pleased to see volume growth of 19%, and CupPak is also up 20%. Pharma, of course, is at 900%, though that’s off a small base. On pharma, though, if you compare with last quarter, when INR 7.42 crore was done, we’ve now done INR 10.8 crore — that’s almost 46% growth in value terms and roughly 35% growth in tonnage terms. It shows we’re even achieving better pricing on pharma products this quarter than we did last quarter.
Got it, that's really useful. There's just one final point I'd like to tack onto that question. Are we noticing any softening in demand from, say, players such as Opus — the ones fueling growth in the paint sector? Or does it look balanced across every player?
Things are pretty even everywhere else besides Birla Opus, since Birla Opus is still on a growth path. As a matter of fact, we saw quite encouraging growth this quarter too. Value terms were up roughly 16%, and 17%.
That's specifically for Opus, sir?
Just for Grasim, yeah.
All right, got it. So there isn’t any particular slowdown, as it were?
There's definitely a slowdown happening. Everyone else is either flat or in negative territory.
Right, but that doesn't apply to Opus.
As far as our sales to Opus go, they are the sole one — and those sales have increased quite impressively.
Got it. Sir, that’s really useful. I’ll get back into the question queue in case there are any more questions.
Alright.
Thanks. Our following question is from Darshita of DSP Asset Managers. Kindly proceed.
Yeah. Thank you, Lakshmana sir, for the chance. My first question was about EBITDA per kg. Even though we saw a better mix from first quarter to second quarter, our EBITDA per kg has dropped from INR 41 to INR 39. Are we seeing any decline in EBITDA per kg within the F&F space? Is there pressure there, or is it mostly due to lower volume growth?
The reason comes down to weaker volume growth as well as reduced capacity utilization. During Q1, utilization reached 74%, but in Q2 it has fallen to 63%. Naturally, all of the overheads are going to rise, and that puts pressure on EBITDA.
Alright.
Normally, Q2 wouldn’t be that rough, but with severe rains hitting several regions right now and the Goods and Services Tax announcement, business slowed down this quarter, and that hurt capacity utilization. Once capacity utilization drops, costs naturally rise, and that weighs on EBITDA. Still, I’m very pleased it’s significantly improved from where it stood a year ago. Last year it was just INR 36.38, and now it has risen to INR 39.4. That’s a gain of nearly INR 3. The main driver there is pharma and food products.
Understood. Next, inside our paints segment, could you tell us what contribution we get from Asian Paints and ABG, compared with what it was in the second quarter of 2025?
Looking at the period from the second quarter of 2025 through the second quarter of 2026, Asian Paints is roughly flat. Volume movement is perhaps 2% or 3% either way, yet Grasim shows a sizable increase of roughly 17%-20%.
Mm. But what share of our total paints sales comes from them?
When it comes to the overall paints category, I don't have that precise figure.
No, just an idea is fine.
Asian Paints is going to stay above 60%, and Grasim could come in at roughly 20%, 25%. And the remainder—
Okay.
... those being AkzoNobel, Berger, and KNP.
Did that 25% figure rise compared with a year earlier?
Yeah, absolutely. Sales were much lower a year ago. So they've really climbed quite a bit. 24%.
Understood. My apologies if someone has already raised this, but do we still feel confident about hitting the INR 90 crore pharma revenue figure we were expecting? As I recall, we had previously provided guidance close to that number. Are we still on—
No, I believe that was misheard. INR 90 crore was never mentioned by me. A year ago the figure was barely INR 8 crore to INR 9 crore, while for this year we've guided to INR 35 crore to INR 40 crore.
No, that’s for 2028. Not for 2026.
Oh, 2028. Yeah.
Yeah.
For 2028, INR 90 crore isn't a big deal. In fact, this year itself, we may go past our INR 35 crore target.
Understood.
Since we're already at just over 10% for this quarter — and even if that same trend holds through the following two quarters, because the new product will come on stream in Q1. Certain molds arrive in Q4. A few molds land this month and the next, trial supplies will follow, and commercial supplies get underway in Q4. Even supposing we keep doing INR 10 crore across the next two quarters, we'd close at INR 35 crore to INR 37 crore, which sits above our INR 35 crore target. For next year, we're aiming at roughly INR 55 crore to INR 60 crore. With the new molds arriving and turning productive, I think we ought to get there. 2027, 2028, yes. Once more, we foresee growth of another 40% to 50%, which puts us in the vicinity of the INR 80 to INR 90 bracket.
Understood. For the pharma segment, EBITDA per kg is going to stay in the neighborhood of INR 100-odd. That is, roughly INR 100 to INR 120, and to be conservative, INR 100.
Yes, of course.
Understood. Excellent. Appreciate your handling every one of my questions. Best of luck.
Thanks.
Thanks. Our following question is from Shirish Pardeshi of Motilal Oswal. Go ahead, please.
Hello, sir. Good afternoon, and thank you for the chance to follow up. On pharma, the growth is tremendous, and you sound very strongly convinced. Which product in particular is driving it? Is it canister that's driving this growth, or are the caps and bottles behind it?
Right now, growth is being driven by our EV tubes, caps, and bottles. Canister has just begun to pick up a couple of orders from clients I'd rather not name — at least two or three of them. Some bulk supplies are also happening this month. Once canisters really take off, the profitability figures would still improve, even if not the top line. But keeping that at a conservative level, the growth is still coming from EV tubes and bottles and caps.
Alright, just to follow up on that — one of the big customers that was running the stability test and pilot, has that customer actually started placing official orders with us?
Yes. Actually, there are two such clients — both strategic, and each has the potential to reach at least INR 10+ crore in annual revenue. Both have begun placing small orders — I wouldn't describe them as huge — but at minimum orders in the region of INR 70 lakh, INR 50 lakh to INR 80 lakh, spread across the coming two to three months. Those orders came in only during September and are currently being fulfilled this quarter. The contribution will build gradually. In Q4, at least in my view, each of them will bring in no less than INR 2 crore to INR 3 crore per quarter.
Alright.
That potential is going to be realized in Q4.
For my second question, I'd like to ask about the capacity enhancement at Grasim. Cheyyar and Panipat are now fully operational. Do you plan any further capacity additions, and what was the capacity utilization at these two plants at the end of quarter two?
For ABG, the total capacity we're building across all three plants combined comes to roughly 10,000 tons. In this quarter we've done 1,500 tons, and — sorry, what was the figure? About 2,900 tons in H1. So we'll likely land at 6,000-plus tons of utilization out of the 10,000 tons installed. That means somewhere around 60%-65% will probably be utilized.
That’s really useful. The other thing I wanted to ask about — you said in the press release that you’ve brought in the next-gen IML molding, which actually lowers production cost. Is this project fully stabilized, or are there still some more things to do on it? How much cost reduction does this deliver, and what share of revenue are you aiming for in FY 2026?
As I mentioned on my previous call, that's what I was referring to with the IML integration. All IML operations have now been consolidated under a single roof at Sultanpur. On top of that, we're producing the HTL labels in-house, and that's where we expect the integration benefits to show up, possibly beginning at any point now. In July — just last month — and August, we shut down our Jeedimetla unit and moved the machinery over to Sultanpur, Hyderabad. Operations there got going in August and September. You'll likely see the cost-reduction benefits from IML manufacturing start to accrue from Q3 and Q4.
What sort of cost reduction percentage are we talking about — roughly 7%, 8%, or 10%?
On the consumable cost side, yes — not on total revenue. It'll show up in consumables, which run at roughly INR 22 per kg. You could likely see a benefit of about a rupee.
Right. So that'll contribute more in FY 2026?
Right, of course. You're referring to FY 2027 there. We're talking about FY 2026.
Right, fiscal 2027 — my apologies.
Yes. It's going to add more in FY 2027.
Alright, the final question. You said that during a soft quarter, volumes come in lower, and that has shown up in EBITDA per kg. You also said this is going to disappear. I mean, I’m not placing too much weight on the paint, but at last Panipat has begun rolling. Does that give you confidence that we can hold INR 40+ per kg in the second half?
Yes, I'm confident we can hold INR 40+ even in the second half. Q3 might look a lot like Q2, but Q4 should climb back to somewhere near Q1 levels. So we'll finish at INR 40+.
Alright.
... across the entire year. Compared with INR 37.6 during the prior year. That works out to an EBITDA gain of nearly 6%, 7%.
Okay. Thank you, sir, and best of luck. I have a few questions. I’ll come back in between.
Appreciate it.
Thanks. Our following question is from Shubham Jhawar at Dexter Capital Advisors Private Limited. Go ahead, please.
Can everyone hear me?
Yes, sir, we can hear you.
Hello, and thanks for taking my question. I really just have one item I wanted to ask about. When I look at realizations per kilo in our Food & FMCG business for this quarter, they come in at roughly INR 295, correct? That figure previously stood at about INR 330 to INR 340, and since FY 2022 it has been drifting lower, so it now sits under INR 300 per kilo. Sir, looking ahead, what should we expect for realizations in Food & FMCG? Is there any specific reason this quarter's number fell below INR 300?
Look, there's certainly some competitive pressure emerging in certain segments of Food & FMCG. I even mentioned this during the last quarter as well. A handful of smaller players have entered various parts of the country, and they're definitely creating some competition. And since we're fully centralized in Hyderabad and ship every product nationwide from that single location, we face the downside of both delivery delays and freight expenses. Now that Panipat is up and running, and we've already secured a couple of major clients in that area, I'm confident that next season we'll be able to step in and recover our numbers. On pricing, though, yes, there is a bit of a decline in per-kg value within Food & FMCG. Even so, it remains considerably stronger than our other products.
Understood, sir. As for my second question, I realize ABG volumes have begun rising from FY 2026 onward, but I wanted to get a handle on the demand forecast they provided us during the previous fiscal year. So is demand sitting within that same range, or has it come in below what they told us last fiscal year?
April and May were sluggish at first, though things then improved fairly well. In October, however, everyone saw a bit of a decline, since the festival arrived early and there were many holidays that month. As a result, most paint companies are roughly flat for October, yet their forecasts for November look quite strong. So I believe their figures will begin to get better.
Got it, sir. That came from my side. Thanks.
Thanks. Our next question is from Jaiveer Shekhawat at Ambit Capital. Please go ahead.
Thanks for taking my question. Mr. Rao, you said Grasim did almost 900,000 tons in the first half. Is that correct?
Regarding Grasim, no. What I mentioned is that we achieved roughly 2,900 tons during the first half, and therefore our expectation for the entire year is somewhere between 6,000 tons and 6,500 tons.
That figure is specifically for Grasim — 2,900 tons, is that right?
Yes.
If we were to look at this on an annual basis, sir, that comes out to approximately 6,000 tons of volume, as you're describing.
Yeah.
In the paint segment last year, volume came to almost roughly 18,000 tons. So are you saying that if we finish the year at around 20,500 tons or 21,000 tons of volume, then the remainder of that segment — everything apart from Grasim — would be down by nearly 15%-20%? Is that the correct way to read it?
Not really. The decline for Asian Paints won't be that large. For us, at least, it's barely a 2%, 3% drop. With Akzo as well, the drop isn't significant. In fact, it's flattish, at zero. KNP too — only 4% growth. It's not a given that numbers will fall for other peers. The dip at Asian Paints itself appears large because they account for a very big chunk of our paint sales. That's why you might see overall growth looking tepid this Q2. Looking at H1, paint volumes are still up by about 12%.
I’m just trying to get a clearer picture. In the prior-year base—FY 2025—what volumes did Grasim record? And apart from Grasim, what growth is occurring in the paint segment? That’s really the point I’m trying to reach.
The first one I’m able to address — that’s Grasim’s growth — but as for all the rest, I’m not in a position to provide the details.
Sure.
Grasim has increased from, let's put it this way, 1,250 tons in Q2 of this year, up from 995 tons a year earlier. That works out to 24% growth for the quarter. For the half year, it stood at 1,560 tons last year and now sits at 2,900 tons. That represents roughly 86% growth.
Got it. As you correctly noted, aside from Grasim, growth has been fairly tepid, I'd say. Regarding the guidance you mentioned earlier for volume growth — roughly 12%-15% — you've managed about 12% in the first half. Are you holding to that, or will there be a downward revision?
We intend to accomplish that. I believe we might at minimum hold to 12%, since, as I mentioned, the volume increase will likely be concentrated more in pharma and Food & FMCG. Measured in tons, we could still record growth near 12%. However, measured by sale value, our goal is to reach at minimum the 12%-15% range. That currently stands at 13.88% for the first half. On a sale value basis, we will remain within 12%-15%. On a volume growth basis, we will be attempting to sustain 12%. I think that is achievable.
Finally, about the Panipat F&F expansion — is it up and running? Have you also begun getting bigger orders over there? And what's the capacity utilization for it?
Yes. Right now capacity utilization is minimal, given that the facility is brand new. So far in October we've booked roughly INR 40 lakh in sales. That's a very small amount. But things are starting to pick up, and we've signed one significant contract — I'm not able to share the specifics. From that single client, we should gain at minimum INR 4 crore to INR 5 crore in turnover in the next financial year. Manufacturing of the molds is underway. They should be ready and operational starting in February. That will be a major boost for Food & FMCG out of Panipat. A number of small and medium orders are also flowing in. I'm confident that in the next season — Q1 of next year — we'll see a worthwhile contribution from Panipat via F&F.
On the F&F side overall, should we expect you to keep up that 15%-20% growth? That's also something you'd already guided the market on earlier. Does any of that shift at all, or do you believe you can hold onto it?
No, we still feel good about keeping growth at 15%-20%.
Got it.
Over the six-month period, the figure stands at 17% at this point.
No, I mean, even in the year ahead too, 2027 and 2028. Do you think the capacity you have will be enough in—
While I can't commit to 2028, 2027 at least is something we can speak to, since Panipat will begin delivering strongly that year — and probably in 2028 as well, though 2027 is the certain one.
Got it. Of course, sir. Thanks very much, and best wishes to you.
Appreciate it.
Thanks. Our next question is from Chirag with Keynote Capitals. Please go ahead.
Thanks for giving me the chance. Lakshmana, sir, my first question concerns the volume, value, and mix of IML versus non-IML for Q2 FY 2026.
Yes, I think they've gotten even better since then. Coming out of Q1, it barely budged. IML plus other label HTL came in at 75.02%, and now that figure stands at 75.11%. So it has only shifted slightly.
Was that in terms of volume?
Yeah, in terms of volume.
How about value terms?
On value terms, it's roughly comparable. Last year it was 77%. Right now it's 76.2%.
Alright.
Regarding the previous quarter and Q4.
Understood — I overlooked a response from one of the earlier participants, and it concerned a decline in realization for the FNS segments. Would you mind repeating that one time?
The way he described it, the decline was quite small. In Q1 it stood at INR 309 per kg, while in Q2 it's roughly INR 300. Shifts in the product mix, along with a bit of competition in nuts and garnish, are what account for the reason I gave. So Q1 had it at INR 309. In Q2 it has now landed at INR 300, INR 301, or thereabouts. That, I believe, is what he meant.
Understood, sir. My final question concerns the notable decline in the lubes segment. You said rainfall was the primary cause. May I expect the previous run rate of more than 2,000 in volumes on a quarterly basis to return, specifically for lubes, and for paints, is that expected to come back to the 4,800 tons to 5,000 tons per quarter level?
On paints, I'm confident, but when it comes to lubes I remain skeptical, because it's unclear whether goods movement will pick up with the Goods and Services Tax reduction, which could drive lube growth. As I said, lubricants keep delivering more and more mileage per liter. Certainly, even though the economy is growing in terms of goods movement, lubricant consumption might not rise in tandem. There will probably still be a lag in lubricant growth. That's my view. With paints, though, once the rains subside, people badly need it now, since the rains wash away whatever paint is already there or isn't there. Paint movement will definitely pick up in the months ahead once the rains subside.
Understood, sir. Do you have any direction to offer regarding CapEx moving forward?
CapEx remains robust, yes. We've already finished INR 60 crore, and on an annual basis there's another INR 30 crore, INR 35 crore. We'll likely wrap up this year at roughly INR 100 crore of CapEx as well, lower than the INR 140 crore, INR 130 crore levels of the past 2 years. Across the last 3 years it averaged about INR 140 crore. So this current year will probably come in near INR 105 crore.
How much of that is maintenance CapEx?
What exactly is what?
Could you tell me what maintenance CapEx is?
So maintenance is going to stay roughly in line with depreciation, and that comes to about INR 35 crore to INR 40 crore each year. We'll keep replacing machinery, robots and molds as before, and beyond that the spending goes toward extra capacity, mainly in pharma, plus balancing capacity at the ABG plants.
That covers everything on my end. Thanks very much.
Back in the first quarter, we had already put money into land for the pharma expansion — roughly INR 11 crore.
Yes.
We picked up 2.5 acres right next to our Sultanpur facility. That's the sole greenfield expansion we have. It could take place within the coming year. Beyond that, everything else is going to be brownfield — meaning we'll be adding machinery to match demand.
Okay, so they anticipate that this will boost capacity from 1,500 tons up to 3,000 tons, is that right? For pharma.
Roughly 2,500 tons—
Two thousand five hundred tons.
And that's going to unfold over the course of the next financial year. This is a gradual progression — it won't all take place in one shot.
Okay.
Most likely in Q4, we'll raise it from where it stands now up to one level higher, and then around July — that's the second quarter — we'll bring on additional capacity in ophthalmic and other lines. So it will get to that level step by step.
That's everything from me. Thanks.
Thanks. Just a quick reminder for everyone: if you'd like to ask a question, you can press Star and One on your touchtone phone. Our next question is from Pratyush, an Individual Investor. Please go ahead.
Hello there. Can you hear me okay?
Sure, Pratyush.
Yeah. Hi, sir. I basically have 3three questions. First, on the pharma segment: I think last quarter you gave guidance that around 12 or 15 clients were in the pipeline at various approval stages. Could you please update us on how many have been approved and how many clients will be onboarded in the current financial year?
I don’t have a ready answer for that. I believe the total number of clients actually taking part in our sales is now over 20, 25 at this point. In this current quarter, I haven’t counted, but probably there are at least five to six additions. Some of them we’ve been working with for the last seven, eight months on various trials. So they began placing small commercial orders. Prominent among them are Laurus and MSN. So they’ve started picking up small commercial orders. I wouldn’t call them huge, but they have huge potential, and since they are local, they’ll have an advantage in capturing the demand.
When you provided the pharma guidance, was that assumption based solely on receiving orders from existing clients? Or what kind of vendor additions or client additions were assumed when you arrived at that revenue guidance?
Sure — so this comes from marketing feedback. What they're seeing is that a number of these accounts that are in trials could potentially turn commercial. And some that have only just finished their audit may begin placing trial orders. This is a process that keeps moving forward, and these things build on each other. The reason is that once a company generally takes on a supplier, they stay with that supplier. Like I mentioned previously, our innovation and our ability to come up with fast solutions for our clients are why they're choosing us as their supplier. And once we're in as the supplier for one specific product, they're free to hand us any other product as well — provided we meet the price and the quality. So beyond that, getting your name onto a pharma company's supplier list is hard. Once you're in there, it comes down to your relationships, your quality and your timeliness that let you bring in more and more orders.
All right, sir. And one more thing — at this point, the pharma guidance reflects only the Brownfield expansion, correct? Nothing that would count as entirely new CapEx is included in that, is it?
Not at this point. Not for this year, and not even for next year. That steady increase we're setting in motion so we can hit full capacity by the close of this financial year—that is, March, April—should let us handle roughly 55%-60% of next year's demand, which is what I projected. Beyond that, we require an extra facility; we've already bought land for it, and it will likely come online around July, August next year. Still, I'm not factoring in much contribution from that added capacity during the coming financial year.
Okay, so on pharma specifically, there are basically two streams, correct? One was a bottle, and one was a cap. I just wanted to get a sense of whether those two products are connected, and whether we should expect the volume growth for both of them to always move together? Or are they actually unrelated products? And if they are unrelated, what share of pharma sales should each of these products be expected to account for?
To start with, it isn't a single bottle and a single cap. Bottles come in multiple varieties — over 40 of them. At this point we've already made molds for more than 40 bottle varieties, and caps come in at least 8 to 10 varieties. Not just the plain caps you'd see on tablet packs — they also go on eye droppers or certain cough drops. Along those lines, we've begun producing various cap applications, with some in the trial stage and others in testing. What we sell right now is standard bottles and caps, child-resistant caps and EV tubes, and those are the main contributors to our sales as of today. The count of bottle varieties is quite large — above 40, and it could reach 50. We'll talk again next time. That's how we're able to grow our product range quickly and rapidly. Still, the bulk of sales continues to come from EV tubes plus bottles and caps. A small portion comes from canisters.
Yes, sir. And one more thing, sir — could you possibly share the volume figures for paints and for goods applied to paints, both for this quarter and the one before it?
I don’t have the figure for paint by itself, but for paints overall—yes, paint alone, I do have it. In Q2, we reported 4,688. Is that right? Sorry—4,845. Paint sales came to 4,845 tons out of 10,000 tons.
Sir, what about the quarter before this one?
In the prior quarter, that figure stood at 5,593 tons.
Alright, final question. Could you share what the optimal capacity utilization is for each of the business segments — pharma, paint, all of them?
Look, ideal is always 100%, but nobody can get there because, as I mentioned previously, machines built for bottles or jars deliver greater productivity than the ones for caps. The reason is that caps are always lightweight, yet they require comparable machines owing to the surface area. When you work out capacity utilization in injection molding, crossing 75%-80% is genuinely excellent. So last quarter we sat at roughly 74%, but during this quarter that figure fell to 63%. Thus, across the six months, it comes to 69%.
Understood, sir. Thanks.
Thanks. Our following question is from Pratham at Quantum AMC Private Limited. You have the floor.
Yes, madam.
Pratham, go right ahead with your question.
Right, so you were just saying that a few new products are getting added.
Pratham, we can't hear you. Could you turn up your volume?
Right, so I was referring to the fact that you've introduced a few new products in the pharma segment. Does this basically enlarge the INR 5,000 crore TAM we discussed earlier, or do those products already fall inside that TAM estimate?
Could you explain what the INR 5,000 figure refers to?
A total addressable market of INR 5,000 crore, a figure we referred to on earlier calls.
Are you asking about total demand across the whole country?
Yes, demand from pharma.
Yes. Total demand in pharma packaging sits at roughly that level, though the items we produce also fall within that same universe. A portion of them are innovative by nature. Others are simply replicas or replacements for those kinds of products. Given this, we won't be altering the market's overall size, but it will certainly secure us a slice of market share.
Alright, that's everything from me. Thanks.
Alright.
Thanks. Our following question is from Sandeep Modi, an Individual Investor. Please proceed.
Yeah. Can you hear me okay?
Yes.
Yeah, sir, we can hear you.
Right, yes sir. I just had one question I wanted to ask. There was some case going on about copying certain products, patent rights, and so on. Did we receive any compensation for that?
Look, we don't receive any compensation from courts or anyone else. At most, we can make them halt production and take their molds. That's what we did with two or three companies that were violating. We don't get any compensation.
All right, one more question, sir. Altogether, what number of pharma companies have come to see our facilities? How many of them are currently active, and is there any positive update on the pharma side, and so on?
Yes. There are over 60 — I believe 50, at minimum. More than 50 have visited, and no fewer than 20, 25 have begun purchasing from us in small or medium quantities. Not one of them accounts for 100% or 20% of the sale. Everyone is spread out, so to speak, with the largest sale at maybe 10%, my biggest client, perhaps in EV tubes. Turning to bottles and caps, we've now begun with at least seven or eight reasonably sized clients, and those figures for them will land somewhere near INR 25 lakh-INR 30 lakh per month each. Those numbers will begin building up as we move forward.
Alright.
The other 30 clients that have been to our audited facilities gave their approval as well, though the commercial terms and trial runs are going to need a few additional quarters.
So, how are things progressing with the pump business?
Pump isn't doing great. We're not seeing a lot of major traction, but it's still on the plus side. We can sell roughly INR 30 lakh-INR 40 lakh worth of goods to both the pharma side and the cosmetic side.
All right. Have any export orders been canceled because of the tariff and so on?
Not really. At least up to now, we haven't been major exporters to the U.S.A. We sell only around INR 2 crore to INR 3 crore each year.
Alright.
And that continues no matter what happens with the tariff. Perhaps they thought we would shave our price by 4% or 5%, and we are doing that as well. But as of right now, it's a negligible factor.
All right, regarding the land that we've purchased — at what point will it be completely equipped with robots and so on, and begin manufacturing for pharma?
No, there won't be robots in pharma. Robotics is used only for EV tubes, and we don't intend to bring in additional robots for EV tubes in pharma. What we currently have is enough. As for the new facility, we haven't yet obtained plan approval, since the land was acquired just three, four months ago. We have now submitted our application for plan approvals. We'll likely receive it in December, and hopefully construction work will begin in December, January. During the next financial year — perhaps the second half, or July, August — we should be able to get it into shape. And as I said earlier in my answer, those quantities and capacities are not included in next year's predictions.
All right. And sir, how’s Birla Opus performing?
As far as we're concerned, Birla Opus is performing well. They're delivering solid growth for us.
Alright. Thanks a lot, sir.
Thanks. Appreciate it.
Thanks. Our next question is from Varun Singh at PMS. Go right ahead.
Hello there. Appreciate the chance to ask, sir. I just want to get some clarity on that 12% volume growth you mentioned — did you mean that figure applies solely to the paint business, or is it for overall volume?
Nope. Not overall volume.
On the overall volume — okay. And secondly, for the second half, would it be reasonable to expect a 4%-5% improvement in realization? Because in the first half, sir, we saw roughly a 3%-4% improvement in overall realization. That said, I think the base in 1Q FY 2025 was more favorable, since realization at that point was INR 200 per kg.
The INR 200 or INR 203 figure isn't what drives this. Once again, it comes down to how raw materials are priced.
Yeah.
That's going to come down to product mix. The product mix—
When it comes to the mix of products.
When Food & FMCG plus pharma goes up, realization per kg goes up as well. So the 8.3% you mentioned is the growth in EBITDA margin for H1. I believe we'll keep seeing something in that vicinity and turn in an EBITDA margin of INR 42, INR 41 even in H2.
Alright.
That figure stood at INR 37.6 across the prior full year. So we're seeing a substantial step up of over INR 3 — at minimum INR 3 — in EBITDA per kg.
Okay, so for the second half, an EBITDA of roughly INR 42 to INR 43 per kg is a fair assumption. Would that be right, sir?
Nope.
Even what we're expecting for INR 41.
In the second half of last year, it was barely INR 37, INR 38. So on that—
Yeah.
If we take 5% to 6% growth as the assumption, then for H2 we could land in the INR 40 to INR 41 range. That puts the full year somewhere near the INR 40.70 mark, which is an increase of over INR 3 versus the INR 37.6 recorded in the prior full year.
Right. But in that case, I think we'd be cutting or reducing our guidance note from INR 42 down to INR 40.75.
No, what I said was that our guidance is INR 40 to INR 42, depending on growth. Given the tepid growth in Q2, we think we'll still land at INR 40.7, or maybe INR 41 at best.
Got it. And sir, a final question from me about GST and the uncertainty around shipments. Those benefits will carry into the current quarter, Q3. So with that in mind — and of course, I think the rain and the cyclone in Andhra will play a part — do you still consider 12% volume growth for Q3 a reasonable sort of assumption, or do you think that figure is too high?
My sense is that Q3 could see growth along the lines of what we had in Q2, though once we get to Q4, I'm confident we'll clearly be posting double-digit growth.
Overall, we saw volume growth in the double digits.
If we look at seasonality, the third quarter comes in at the lowest level. The second and third quarters are the weaker months from a seasonal standpoint. What provides some support is—
Yeah.
Regarding the growth we're seeing in pharma and in the food sector in the North, hopefully profitability will stay intact. As for volume growth expectations in Q3, I'd say it would be close to what we saw in Q2. And in Q4, it will definitely return to double digit.
Got it. All right, sir. Of course. Many thanks, and I wish you the very best.
Thanks.
Thanks. Our next question is from Vishwa at PL Capital. Go ahead.
Yeah. Can you hear me okay?
Yeah, we can hear you.
Yes. I had a comparable question regarding EBITDA per kg for the second half, so that has already been addressed. Thank you.
Thanks. Our next question is from Sanyam Shah at Solidarity Advisors. Go ahead, please.
Hello, sir, and thanks for giving me the chance to ask. I’d just like to get a sense of the steady-state EBITDA per kg we should expect for the Food & FMCG segment. Also, does that figure take into account the realizations that are declining, which you’re currently seeing?
Yes, I did address that. In Food & FMCG, realization per kg has dipped slightly, since competition is intensifying in certain corners of the markets. We can manage this effectively, at least where growth is concerned, through our plant in the North, which will help reduce supply costs and supply time across the northern region. A 19.54% increase for Q2 and 16.97% — nearly 17% growth in H1 — is very encouraging for us. Once our north plant begins operations, we will be able to sustain that momentum. And while EBITDA per kg in food may take a dip, the overall growth rate of 17% is genuinely heartening.
I'd just like to get a handle on this, sir — what would the steady-state figure be, the normalized figure, for EBITDA per kg?
There isn't any—
Now, let's move on to Food & FMCG.
Regarding food and FMCG, segment-level figures aren't available at this point, though that should stay somewhere around INR 70 to INR 75 per kg. Earlier it was likely INR 75 to INR 80. So INR 3 or INR 4 per kg of EBITDA may have declined in food and FMCG. But, as I mentioned, volume growth should offset this via improved utilization, and that can—
Alright.
… keep the EBITDA going.
All right, sir. And sir, regarding the pharma segment, when we get that capacity up to 2,500 tons, what's the peak revenue we could achieve at that level?
You can probably figure roughly INR 350 to INR 360 for each kg as the sale value, so likely somewhere around—
Alright.
The range is INR 85 crore to INR 90 crore.
Alright, sir, if I look a bit further ahead — say, specifically at the pharma business, maybe 4 to 5 years from now, FY 2030 or FY 2031 — do you believe that for us, pharma could become a business of INR 150 crore to INR 180 crore in revenue terms?
It’s a long-term perspective we’re offering here, though of course that can happen.
Right.
Five years from now, those numbers are certainly something we're examining.
Alright, sir, I’ve got nothing further from me. Thanks.
Thanks.
Thank you. Since participants have no more questions, I'll now pass the conference to management for their closing remarks.
I want to use this chance to thank each person who expressed interest in joining the concall for our Q2 and H1 results. As the company intends to expand geographically and strengthen growth by segment in Food & FMCG and pharma, I'm certain the future appears promising. Improved utilization once the rains let up, along with demand rising thanks to the Goods and Services Tax reduction, ought to lift the numbers going forward. I wish every one of you a very happy evening and a good future. See you later. Bye bye. Thanks.
That brings this conference to a close on behalf of Emkay Global Financial Services Limited. We appreciate your participation, and you can go ahead and disconnect your lines at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Mold-Tek Packaging Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Mold-Tek Packaging Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.